VISTA as a regulator of antitumor immunity (3) by inhibiting T lymphocytes (4) was found to be highly expressed in several cancers such as ovarian cancer, endometrial cancer, gestational trophoblastic neoplasia and triple-negative breast cancer (TNBC) (3, 5, 6). This evidence concerns the gene VSIR and ovarian carcinoma.